The Center for Drug Addiction Policy was started by David Aden, who serves as its editor-in-chief. By trade, Mr. Aden is a technologist and writer, primarily covering high tech. He has had a long term interest in drugs and drug abuse, initially kicked off by his own encounters with drugs and drug abuse among his friends as a teenager, reinforced later by his close friendship with several people who worked in drug education and rehabilitation.
Over the last several years he’s taken an active interest in drug abuse policy issues including the unintended consequences of marijuana law liberalization and the tragedy surrounding the opioid crisis. His areas of interest include both illegal and legal drug abuse, particularly the outsized explosion in prescription drug use that targets vulnerable and “available” market groups such as children, the elderly, the military and those suffering loss or other real-life problems.
In the early part of 2017, he began to look into the political, financial and regulatory impact of a seemingly new breed of drug addiction solutions that were making their way into prominence with policy makers and governments, Medication-Assisted Treatment (MAT). Mr. Aden noticed that although it seemed likely that MAT would have a place in a full array of treatment and rehabilitation options, it also was clear that it came with some dangers that had not been fully explored. Because Mr. Aden felt that our entire history of drug and drug abuse policy has been pockmarked by tragedies caused by “unintended consequences,” he concluded we would be well advised to more carefully examine the sometimes strong-arm insistence on MAT as the final “solution” to drug addiction.
He founded the Center for the Study of Drug Addiction Policy as a means to bring together data on drug policy, to examine marketing claims that addiction is just a physical disease and to explore the growing reliance on MAT. The Center’s mandate is to critically examine current trends so as to assist the public debate aimed at identifying and formulating policies that might help alleviate the opioid crisis while minimizing any unintended consequences.